European Parliament Explains ‘Vanishing’ Study On Balancing Access & Innovation In EU
Changes are being made to a prematurely published study that proposes an EU drug procurement authority, a centralized pharmaceutical fund and a European pharmaceutical R&D infrastructure to match public health needs with R&D investment.
You may also be interested in...
Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.
The rapporteur for the draft directive that is part of the proposed EU legislative revision package says the pharmaceutical industry needs certainty and long-term predictability regarding the expected level of regulatory data protection. But her proposal to increase the RDP period is not shared by the rapporteur for the draft regulation.
A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time.